Program
filgotinib maleate
Its studies are mostly in Colitis, Ulcerative · Arthritis, Rheumatoid, led by Eisai.
Furthest: phase 4, since Sep 30, 20242 company-led studies, 1 open or runningNext primary completion: Nov 30, 2027 (phase 4)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisai | 21 open or running | phase 4since Sep 30, 2024 | Sep 30, 2024 | Nov 30, 2027phase 4 · NCT06964113 |
Also a collaborator on its studies: Gilead Sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 30, 2024First study: phase 4 study in Arthritis, RheumatoidFirst studyNCT06625242 · 118 enrolled · South Korea
- May 2, 2025Phase 4 study in Colitis, UlcerativeNCT06964113 · 94 enrolled · South Korea
Ahead
- Nov 30, 2027Primary completion: phase 4 study in Colitis, UlcerativeNCT06964113
TargetBeta
“The maleate form of filgotinib, an orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06964113Colitis, Ulcerative · South Korea | 4 | Active, not recruiting | Nov 30, 2027 | 94 |
| NCT06625242Arthritis, Rheumatoid · South Korea | 4 | Completed | Jan 21, 2026 | 118 |
How it is read
Names in the registry
- “Filgotinib Maleate”, 2 entries
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.